Ointment to Prevent Scar After Thyroidectomy

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of INV-001 Administration for the Prevention of Scar After Thyroidectomy

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05838833

Enrollment

Registered

2023-05-03

Start date

2023-02-14

Completion date

2024-06-30

Last updated

2023-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scar

Brief summary

The goal of this study is to evaluate the efficacy and Safety of INV-001 administration for the prevention of scar after thyroidectomy. Participants will be asked to apply ointment on their scar for 12 weeks.

Detailed description

to evaluate the efficacy -investigator check POSAS and VSS

Interventions

DRUGINV-001

Patient will be assigned to one of three arms.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient who got thyroidectomy due to Thyroid cancer * has scar longer than 3 cm

Exclusion criteria

* have history about Keloid or Hypertrophic scar * have infection on surgical site

Design outcomes

Primary

Measure	Time frame	Description
Observer overall opinion of POSAS	12 weeks	POSAS POSAS: Patient Observer Scar Assessment Scale

Secondary

Measure	Time frame	Description
Observer overall opinion of POSAS	3, 6 weeks	POSAS: Patient Observer Scar Assessment Scale

Countries

South Korea

Contacts

Primary ContactMinjeong Kim, Master

mjkim@innovothera.com82-2-6956-8680

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026